Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells
- 1 October 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 50 (4) , 750-755
- https://doi.org/10.1161/hypertensionaha.107.093955
Abstract
Clinical reports indicate that patients with primary aldosteronism commonly have impaired glucose tolerance; however, the relationship between aldosterone and insulin signaling pathway has not been clarified. In this study, we examined the effects of aldosterone treatment on insulin receptor substrate-1 expression and insulin signaling pathway including Akt phosphorylation and glucose uptake in rat vascular smooth muscle cells. Insulin receptor substrate-1 protein expression and Akt phosphorylation were determined by Western blot analysis with anti-insulin receptor substrate-1 and phosphorylated-Akt antibodies, respectively. Glucose metabolism was evaluated using 3 H-labeled 2-deoxy- d -glucose uptake. Aldosterone (1–100 nmol/L) dose-dependently decreased insulin receptor substrate-1 protein expression with a peak at 18 hours (n=4). Aldosterone-induced degradation of insulin receptor substrate-1 was markedly attenuated by treatment with the selective mineralocorticoid receptor antagonist eplerenone (10 μmol/L; n=4). Furthermore, degradation was blocked by the Src inhibitor PP1 (20 μmol/L; n=4). Treatment with antioxidants, N -acetylcysteine (10 mmol/L), or ebselen (40 μmol/L) also attenuated aldosterone-induced insulin receptor substrate-1 degradation (n=4). In addition, proteasome inhibitor MG132 (1 μmol/L) prevented insulin receptor substrate-1 degradation (n=4). Aldosterone treatment abolished insulin-induced Akt phosphorylation (100 nmol/L; 5 minutes; n=4). Furthermore, aldosterone pretreatment decreased insulin-stimulated (100 nmol/L; 60 minutes; n=4) glucose uptake by 50%, which was reversed by eplerenone (10 μmol/L; n=4). These data indicate that aldosterone decreases insulin receptor substrate-1 expression via Src and reactive oxygen species stimulation by proteasome-dependent degradation in vascular smooth muscle cells; thus, aldosterone may be involved in the pathogenesis of vascular insulin resistance via oxidative stress.Keywords
This publication has 32 references indexed in Scilit:
- Molecular Genetics of Experimental Hypertension and the Metabolic SyndromeHypertension, 2007
- Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat HeartsHypertension, 2006
- Oxidative stress and diabetic cardiovascular complicationsFree Radical Biology & Medicine, 2006
- Mechanisms of Reactive Oxygen Species–Dependent Downregulation of Insulin Receptor Substrate-1 by Angiotensin IIArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Mechanisms of Insulin Resistance in Humans and Possible Links With InflammationHypertension, 2005
- Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-SrcHypertension, 2005
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2003
- IRS proteins and the common path to diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2002
- Hypertension, the Potassium Ion and Impaired Carbohydrate ToleranceNew England Journal of Medicine, 1965